{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:45:00Z","timestamp":1775115900403,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012781","name":"MSD K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.clml.2019.05.019","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T17:01:24Z","timestamp":1559235684000},"page":"e581-e587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patients With Malignant Lymphoma and HIV Infection Experiencing Remission After First-Line Treatment Have an Excellent Prognosis"],"prefix":"10.1016","volume":"19","author":[{"given":"Katharina","family":"Kriegsmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia S.","family":"Klee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Hensel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eike C.","family":"Buss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7319-3646","authenticated-orcid":false,"given":"Mark","family":"Kriegsmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Cremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlinde","family":"Egerer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Wuchter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Witzens-Harig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.05.019_bib1","author":"World Health Organization"},{"key":"10.1016\/j.clml.2019.05.019_bib2","author":"Robert Koch Institut"},{"key":"10.1016\/j.clml.2019.05.019_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ejh.13082","article-title":"Malignant lymphoma in the HIV-positive patient","volume":"101","author":"Meister","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2019.05.019_bib4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00277-014-2058-4","article-title":"Therapy of HIV-associated lymphoma\u2014recommendations of the Oncology Working Group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNA), in cooperation with the German AIDS Society (DAIG)","volume":"93","author":"Hentrich","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.05.019_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/oxfordjournals.aje.a114966","article-title":"Temporal trends in the incidence of non-Hodgkin\u2019s lymphoma and selected malignancies in a population with a high incidence of acquired immunodeficiency syndrome (AIDS)","volume":"128","author":"Harnly","year":"1988","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clml.2019.05.019_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0140-6736(82)92740-4","article-title":"Outbreak of Burkitt\u2019s-like lymphoma in homosexual men","volume":"2","author":"Ziegler","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2019.05.019_bib7","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.bjc.6605756","article-title":"Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study","volume":"103","author":"Franceschi","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2019.05.019_bib8","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1097\/QAD.0b013e32832e531c","article-title":"Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy","volume":"23","author":"Bohlius","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.clml.2019.05.019_bib9","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/QAI.0b013e31817efb54","article-title":"Changes in causes of death among adults infected by HIV between 2000 and 2005: The \u201cMortalite 2000 and 2005\u201d surveys (ANRS EN19 and Mortavic)","volume":"48","author":"Lewden","year":"2008","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.clml.2019.05.019_bib10","first-page":"629","article-title":"Incidence and management of AIDS-related lymphoma","volume":"15","author":"Levine","year":"2001","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clml.2019.05.019_bib11","doi-asserted-by":"crossref","first-page":"866","DOI":"10.7326\/M17-2499","article-title":"Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the United States through 2030","volume":"168","author":"Shiels","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2019.05.019_bib12","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.019_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.semnuclmed.2017.09.007","article-title":"PET\/CT in lymphoma: current overview and future directions","volume":"48","author":"Cheson","year":"2018","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.clml.2019.05.019_bib15","doi-asserted-by":"crossref","unstructured":"Kriegsmann K, Wack M, Kriegsmann M, et al. Selective contrast-enhanced computed tomography is appropriate in diffuse large B-cell lymphoma therapy response assessment [e-pub ahead of print]. Eur J Haematol. https:\/\/doi.org\/10.1111\/ejh.13150. accessed June 11, 2019.","DOI":"10.1111\/ejh.13150"},{"key":"10.1016\/j.clml.2019.05.019_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/cam4.178","article-title":"Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition","volume":"3","author":"Ota","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2019.05.019_bib17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/apc.2012.0424","article-title":"Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy","volume":"27","author":"Gotti","year":"2013","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.clml.2019.05.019_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3324\/haematol.11767","article-title":"Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART","volume":"93","author":"Navarro","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.05.019_bib19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jnci\/dji072","article-title":"Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy","volume":"97","author":"Clifford","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2019.05.019_bib20","first-page":"442","article-title":"Acquired immunodeficiency syndrome-related lymphoma: clinical aspects","volume":"27","author":"Levine","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2019.05.019_bib21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/0975-962X.186699","article-title":"Human immunodeficiency virus associated plasmablastic lymphoma: a case report","volume":"7","author":"Desai","year":"2016","journal-title":"Indian J Dent"},{"key":"10.1016\/j.clml.2019.05.019_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/jjco\/hyu012","article-title":"Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan","volume":"44","author":"Kojima","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.019_bib23","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/QAD.0b013e3283635232","article-title":"Association of early HIV viremia with mortality after HIV-associated lymphoma","volume":"27","author":"Gopal","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.clml.2019.05.019_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/QAD.0b013e32834f30fa","article-title":"Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients","volume":"26","author":"Wyen","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.clml.2019.05.019_bib25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jjco\/hym168","article-title":"Report of AIDS-related lymphoma in South Korea","volume":"38","author":"Kim","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.019_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAI.0b013e31802bb5d0","article-title":"Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors","volume":"44","author":"Miralles","year":"2007","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.clml.2019.05.019_bib27","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/annonc\/mdl063","article-title":"Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin\u2019s disease: results of a multicenter study","volume":"17","author":"Hentrich","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.05.019_bib28","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2005-09-3600","article-title":"AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy","volume":"107","author":"Mounier","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.019_bib29","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/cncr.27551","article-title":"Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy","volume":"118","author":"Castillo","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.05.019_bib30","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1200\/JCO.2005.02.9355","article-title":"Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy","volume":"23","author":"Lim","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.019_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.7326\/0003-4819-143-4-200508160-00007","article-title":"A\u00a0prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy","volume":"143","author":"Bower","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2019.05.019_bib32","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdv036","article-title":"Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma","volume":"26","author":"Barta","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501831718X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501831718X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:12Z","timestamp":1761870792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501831718X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S215226501831718X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.05.019","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients With Malignant Lymphoma and HIV Infection Experiencing Remission After First-Line Treatment Have an Excellent Prognosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}